Anti FGF23 antibody and a pharmaceutical composition comprising the same

• US 7,883,705 B2
• Filed: 02/13/2008
• Issued: 02/08/2011
• Est. Priority Date: 02/14/2007
• Status: Active Grant

• Current Assignee: Kyowa Kirin Co., Ltd. (Kirin Holdings Company Limited)
• Original Assignee: Kyowa Hakko Kirin Company Limited (Kirin Holdings Company Limited)
• Inventors: Yamazaki, Yuji, Yamashita, Takeyoshi, Hasegawa, Hisashi, Aono, Yukiko, Shimada, Takashi, Urakawa, Itaru, Yoshida, Hitoshi
• Primary Examiner(s): SKELDING, ZACHARY S
• Application Number:
  US12/030,593
• Publication Number:
  US 20090148461A1
• Time in Patent Office: 1,091 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/12 for electrolyte homeostasis
• CPC Class Codes: A61P 3/14 for calcium homeostasis vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/18 of the parathyroid hormones
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Claims

1. An isolated antibody against human FGF23, comprising a heavy chain variable region or a light chain variable region having the same amino acid sequence as an antibody produced by hybridoma C10 (Accession No. FERM BP-10772).

5. The isolated antibody against human FGF23 of claim 1, wherein the class of the antibody is selected from the group consisting of IgG, IgA, IgE, and IgM.

6. The isolated antibody against human FGF23 of claim 5, wherein the subclass of the IgG antibody is selected from the group consisting of IgG1, IgG2, IgG3, and IgG4.

7. A pharmaceutical composition, comprising as an active ingredient, the isolated antibody against human FGF23 of claim 1.

2. An isolated antibody against human FGF23, comprising a heavy chain variable region comprising an amino acid sequence from the amino acid at position 20 of SEQ ID NO:

12 to the amino acid at position 136 of SEQ ID NO;

12 or a light chain variable region comprising an amino acid sequence from the amino acid at position 23 of SEQ ID NO;

14 to the amino acid at position 128 of SEQ ID NO;

14.

3. The antibody of claim 2, wherein (A) the antibody against human FGF23 comprises a heavy chain variable region and a light chain variable region and (B) the heavy chain variable region comprises an amino acid sequence from the amino acid at position 20 of SEQ ID NO:

12 to the amino acid at position 136 of SEQ ID NO;

12 and the light chain variable region comprises an amino acid sequence from the amino acid at position 23 of SEQ ID NO;

14 to the amino acid at position 128 of SEQ ID NO;

14.

4. An isolated antibody against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

8. A hybridoma C10 (Accession No. FERM BP-10772).

9. An isolated antibody against human FGF23, comprising a heavy chain variable region and a light chain variable region having the same amino acid sequence as an antibody produced by hybridoma C10 (Accession No. FERM BP-10772), wherein the subclass of said antibody is IgG1.

10. An isolated antibody against human FGF23, comprising a heavy chain variable region comprising an amino acid sequence from the amino acid sequence at position 20 of SEQ ID NO:

12 to the amino acid at position 136 of SEQ ID NO;

12 and a light chain variable region comprising an amino acid sequence from the amino acid at position 23 of SEQ ID NO;

14 to the amino acid at position 128 of SEQ ID NO;

14, wherein the subclass of said antibody is IgG1.